Steven P. Gelone - 29 Jan 2022 Form 4 Insider Report for Nabriva Therapeutics plc

Role
President and COO, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
N/A
Transactions as of
29 Jan 2022
Net transactions value
-$1,602
Form type
4
Filing time
01 Feb 2022, 19:44:55 UTC
Previous filing
01 Feb 2022
Next filing
08 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRV Ordinary Shares Tax liability $1,567 -3,483 -0.95% $0.4500 362,540 29 Jan 2022 Direct F1
transaction NBRV Ordinary Shares Tax liability $35.04 -73 -0.02% $0.4800 362,467 31 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.